Conference Calendar

Mark your calendar:

ATS 2017

May 19 - May 24 | Washington, DC

Find more details below ▼

 

 

We can’t wait to meet you at the next conference or convention that Sunovion will be attending in 2017. See the list below to find out where we’ll be and what we’re doing in 2017!

 

January 1-31

 

February 1-28

 

March 1-31

MAR 16-19

AMDA 2017 Conference

The Society for Post-Acute and Long-Term Care Medicine

VISIT CONVENTION WEBSITE

Phoenix Convention Center
North Building
100 North 3rd St
Phoenix, AZ 85004

Booth #301

Exhibit Details

Dates:
March 16 - 17

Hours:
March 16
11:00 AM - 1:45 PM
2:45 PM - 3:45 PM
4:45 PM - 7:00 PM

March 17
10:15 AM - 3:30 PM

Product Theater

Product Theater details coming soon

 

 

April 1-30

 

May 1-31

May 1-3

Spring Hospital Pharmacy Conference

VISIT CONVENTION WEBSITE

The Westin Bonaventure
404 South Figueroa St  
Los Angeles, CA 90071

Booth #709

Exhibit Details

Dates:
May 1-3

Hours:
May 1
12:00 PM – 4:00 PM 

May 2
3:00 PM ‒ 5:00 PM

May 3
8:00 AM ‒ 10:00 AM

May 19-24

ATS 2017

American Thoracic Society

VISIT CONVENTION WEBSITE

Walter E. Washington Convention Center
801 Mt Vernon Pl NW
Washington, DC 20001

COPD Information Booth #1537
Brovana Booth #1837

Exhibit Details

Dates:
May 21‒23

Hours:
May 21
10:30 AM ‒ 3:30 PM

May 22
10:30 AM ‒ 3:30 PM

May 23
10:30 AM ‒ 3:30 PM

Product Theater

Product Theater details coming soon

 

June 1-30

 

July 1-31

 

August 1-31

Aug 31-3

Eastern Pulmonary Conference
August 31 - September 3

Jointly Provided by the American College of Allergy, Asthma, & Immunology (ACAAI) and the Eastern Pulmonary Conference (EPC)

VISIT CONVENTION WEBSITE

The Breakers Palm Beach
1 South County Rd
Palm Beach, FL 33480

Exhibit Details

Dates:
September 1‒2

Product Theater

Product Theater details coming soon

 

September 1-30

 

October 1-31

OCT 4-7

AARC Congress 2017

American Association for Respiratory Care

VISIT CONVENTION WEBSITE

Indianapolis location information coming soon

Booth #627

Exhibit Details

October 5-7, 2017

OCT 16-18

Fall Hospital Pharmacy Conference

VISIT CONVENTION WEBSITE

Hyatt Regency O’Hare
9300 Bryn Mawr Ave
Rosemont, IL 60018

Booth details coming soon

Exhibit Details

Hours:
October 16
12:00 PM ‒ 4:00 PM

October 17
1:15 PM ‒ 3:30 PM

October 18
9:30 AM ‒ 11:30 AM

OCT 28-1

CHEST 2017
October 28 - November 1

American College of Chest Physicians

VISIT CONVENTION WEBSITE

Toronto location details coming soon

Booth #1804

Exhibit Details

Exhibit details coming soon

 

November 1-30

 

December 1-31

DEC 3-7

ASHP 2017 Midyear Clinical Meeting

American Society of Health-System Pharmacists

VISIT CONVENTION WEBSITE

Orlando location details coming soon

Booth #1833

Exhibit Details

Exhibit details coming soon

Product Theater

Product Theater details coming soon

Important Safety Information & Indication

WARNING: ASTHMA-RELATED DEATH

Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including arformoterol, the active ingredient in BROVANA (see WARNINGS). The safety and efficacy of BROVANA in patients with asthma have not been established. All LABA, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication (see CONTRAINDICATIONS).

BROVANA is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers. BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. 

BROVANA should not be used in conjunction with other inhaled, long-acting beta2-agonists. BROVANA should not be used with other medications containing long-acting beta2-agonists. Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms.

All LABA, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication.

As with other inhaled beta2-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, BROVANA should be discontinued immediately and alternative therapy instituted.

BROVANA, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms.

BROVANA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders or thyrotoxicosis; and in patients who are unusually responsive to sympathomimetic amines.

BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.

Overall efficacy of BROVANA was maintained throughout the 12-week trial duration. Some tolerance to the bronchodilator effect of BROVANA was observed after 6 weeks of dosing (at the end of the dosing interval), although the FEV1 improvement remained statistically significant. This was not accompanied by other clinical manifestations of tolerance.

The five most common adverse events reported with frequency ≥2% in patients taking BROVANA, and occurring more frequently than in patients taking placebo, were pain (8% vs 5%), chest pain (7% vs 6%), back pain (6% vs 2%), diarrhea (6% vs 4%), and sinusitis (5% vs 4%).

For additional information, please see the full Prescribing Information including Boxed Warning, and Medication Guide for BROVANA (arformoterol tartrate) Inhalation Solution, at www.sunovionprofile.com/brovana.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Indication
BROVANA® (arformoterol tartrate) Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA is for use by nebulization only.